WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”), a clinical-stage precision oncology company, today announced that Dr. Charles Morris will join the Company as Chief Medical Officer effective, April 20, 2026.
Read more at globenewswire.comPrelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
Provided By GlobeNewswire – Last update: